Xeris Biopharma Holdings Inc
WKN: A3C4ZC / ISIN: US98422E1038Strongbrigde Biopharma 200 Prozent Potential?
11.11.15 20:58
#1
Balu4u
Strongbrigde Biopharma 200 Prozent Potential?
Ausgehend vom aktuell Kurs zum KZ von 21USD
http://www.finanzen.net/analyse/...y-Stifel_Nicolaus__Co__Inc__558835
Pipeline
http://www.strongbridgebio.com/pipeline/
http://www.finanzen.net/analyse/...y-Stifel_Nicolaus__Co__Inc__558835
Pipeline
http://www.strongbridgebio.com/pipeline/
01.02.17 19:40
#3
Balu4u
Kursziel auf 18 USD angehoben!
http://www.finanzen.net/analyse/...rma_Buy-H_C_Wainwright__Co__600398
17.02.17 22:29
#4
Balu4u
Gap bei 3,50 USD
könnte diesen Monat noch geschlossen werden
2,68 USD +0,23 USD +9,18 %
2,68 USD +0,23 USD +9,18 %
02.03.17 18:59
#5
Balu4u
Jetzt aber...?!
http://www.nasdaq.com/de/symbol/sbbp/real-time
02.03.17 19:02
#6
Balu4u
aktuell..SBBP $3.95 * 0.9 29.51%
Kann aber keine News finden! Das Kursziel ist aber sportlich :)
http://www.finanznachrichten.de/...ien/strongbridge-biopharma-plc.htm
http://www.finanznachrichten.de/...ien/strongbridge-biopharma-plc.htm
02.03.17 19:33
#9
Balu4u
Bereits jetzt über 71k bei den Amis...
ist da was im Busch? Hört sich nicht viel an, aber sieht nach Umsatzrekord zumindest für dieses Jahr aus :)
02.03.17 19:40
#10
Balu4u
Und noch 20 Min. Handel in Deutschland
http://www.nasdaq.com/de/symbol/sbbp/real-time
02.03.17 19:56
#12
Balu4u
Die Kuh fliegt...
http://www.nasdaq.com/de/symbol/sbbp/real-time
03.03.17 10:56
#13
Balu4u
Strongbridge Top3
http://www.finanzen.net/top50_ausland/
09.03.17 12:12
#14
Balu4u
Q2 wird sehr interessant werden
http://seekingalpha.com/article/...37th-annual-health-care-conference
16.03.17 22:29
#15
Balu4u
Die Umsätze hier sind echt ein Witz
aber es geht stetig aufwärts
4,10 USD +0,25 USD +6,49 %
4,10 USD +0,25 USD +6,49 %
29.03.17 20:01
#16
Balu4u
Schleicht sich gen Norden...
http://www.nasdaq.com/de/symbol/sbbp/real-time
17.01.18 18:28
#21
Heron
Conference Call Details
http://www.conferencecalltranscripts.org/8/summary/?id=4497144
~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~
~ MACRILEN is Strongbridges Second Commercial Product; Expands the Companys Rare Endocrine Disease Portfolio and Complements its Late-Stage Clinical Development Program for RECORLEV (levoketoconazole) in Endogenous Cushings Syndrome ~
~ Strongbridge Expands Structured Financing Facility with CRG to Support the Anticipated Commercial Launch of MACRILEN in Mid-2018 ~
~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~
~ MACRILEN is Strongbridges Second Commercial Product; Expands the Companys Rare Endocrine Disease Portfolio and Complements its Late-Stage Clinical Development Program for RECORLEV (levoketoconazole) in Endogenous Cushings Syndrome ~
~ Strongbridge Expands Structured Financing Facility with CRG to Support the Anticipated Commercial Launch of MACRILEN in Mid-2018 ~
25.02.18 12:03
#22
Heron
Annual General Meeting
Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
GlobeNewswire•February 23, 2018
https://finance.yahoo.com/news/...plc-announces-annual-123000559.html
Annual General Meeting (AGM) of Shareholders on Tuesday, May 15, 2018 at the offices of Arthur Cox, Ten Earlsfort Terrace, Dublin, Ireland. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 28, 2018.
GlobeNewswire•February 23, 2018
https://finance.yahoo.com/news/...plc-announces-annual-123000559.html
Annual General Meeting (AGM) of Shareholders on Tuesday, May 15, 2018 at the offices of Arthur Cox, Ten Earlsfort Terrace, Dublin, Ireland. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 28, 2018.
Seite:
1

